Intravacc RSV vaccine candidate posts phase I trial results
Intravacc released results of a clinical phase I trial evaluating its live attenuated respiratory syncytial virus (RSV) vaccine candidate. Read More
PerkinElmer launches workstations for COVID-19 detection
PerkinElmer has launched a series of new workstations for SARS-CoV-2 testing. Read More
Memo, Northway to manufacture SARS-CoV-2 antibodies
Swiss biotech company Memo Therapeutics and Northway Biotechpharma plan to collaborate on making a SARS-CoV-2-neutralizing antibody for COVID-19 therapy. Read More
Sanofi to acquire Principia Biopharma for $3.7B
Sanofi has announced that it plans to acquire Principia Biopharma for $3.7 billion. Read More
HiFiBio partners with CoVIC for SARS-CoV-2 antibody therapies
HiFiBio Therapeutics and the Coronavirus Immunotherapy Consortium (CoVIC) will collaborate to develop SARS-CoV-2-neutralizing antibodies with potential therapeutic and prophylactic applications. Read More
Precigen begins clinical trial for HPV-positive tumors
Precigen has dosed the first patients with Prgn-2009, an off-the-shelf investigational immunotherapy candidate, in a phase I/II clinical trial for the treatment of cancers associated with human papillomavirus (HPV). Read More
IsoPlexis partners with Columbia for vaccine development
IsoPlexis is partnering with Columbia University's Division of Infectious Diseases to create a vaccine for COVID-19. IsoPlexis' Single-Cell Secretome immune profiling platform will be used to study cellular drivers of durable and protective immune response to the virus. Read More
Union Therapeutics licenses COVID-19 tech from TFF
Union Therapeutics has completed an agreement with TFF Pharmaceuticals to obtain a worldwide exclusive license for the use of its thin film freezing technology in combination with niclosamide to focus on treatments for COVID-19. Read More
Scipher, Galapagos partner to develop IBD treatments
Small molecule medicine company Galapagos and autoimmune precision medicine firm Scipher Medicine have announced a collaborative agreement to advance novel drug targets for inflammatory bowel disease (IBD). Read More
Anixa, OntoChem identify new anti-SARS-CoV-2 compounds
Anixa Biosciences and OntoChem have identified 26 additional compounds that target the main protease inhibitors of SARS-CoV-2. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
